Results 131 to 140 of about 2,544 (153)

Aptamer-based applications in delivering cancer gene therapies and beyond: state of the art and the missing links to clinical translation. [PDF]

open access: yesAdv Drug Deliv Rev
Coppola G   +7 more
europepmc   +1 more source

Aptamers targeting immune checkpoints for tumor immunotherapy: a comprehensive review. [PDF]

open access: yesFront Oncol
Gedla MK   +6 more
europepmc   +1 more source

The G-quadruplex-forming aptamer AS1411 potently inhibits HIV-1 attachment to the host cell [PDF]

open access: yesInternational Journal of Antimicrobial Agents, 2016
AS1411 is a G-rich aptamer that forms a stable G-quadruplex structure and displays antineoplastic properties both in vitro and in vivo. This oligonucleotide has undergone phase 2 clinical trials. The major molecular target of AS1411 is nucleolin (NCL), a
Rosalba Perrone   +2 more
exaly   +2 more sources

AS1411 aptamer-targeted Gold Nanoclusters Effect on the Enhancement of Radiation Therapy Efficacy in Breast tumor-bearing Mice

open access: yesNanomedicine, 2018
AIM: Herein, the AS1411 aptamer-targeted ultrasmall gold nanoclusters (GNCs) were assessed at different aspects as a radiosensitizer. MATERIALS & METHODS: AS1411 aptamer-conjugated gold nanoclusters (Apt-GNCs) efficacy was evaluated at cancer cells ...
Fatemeh Ghahremani   +2 more
exaly   +2 more sources

Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation

open access: yesMolecular Oncology, 2015
AS1411 is a G‐rich quadruplex‐forming oligodeoxynucleotide that binds specifically to nucleolin, a protein found on the surface and in the cytoplasm of most malignant cells but absent from the surface/cytoplasm of most normal cells.
Matthew Forsthoefel
exaly   +2 more sources
Some of the next articles are maybe not open access.

Related searches:

Interaction study of Dox-incorporated AS1411 aptamer and nucleolin by molecular dynamics simulation

Molecular Simulation, 2023
Pichayanoot Rotkrua   +2 more
exaly  

Home - About - Disclaimer - Privacy